Clinical Trial Update: A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates combining stereotactic body radiotherapy with 177Lu-PSMA-617 to treat prostate cancer; the study is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING